Evidence Snapshot
What this grade covers
Applies to Felypressin's real, current, jurisdiction-documented clinical use as a dental local-anesthetic vasoconstrictor adjuvant: two controlled human RCTs with quantitative, statistically detailed results (PMID 31545671, N=22 crossover; PMID 16044058, N=100, non-dental but directly relevant local-anesthetic-potentiation evidence), one older confirmatory dental clinical trial (PMID 5270027), and direct, current national-regulator/manufacturer product documentation in three named jurisdictions (New Zealand, Australia, United Kingdom). This is real, ongoing, controlled clinical-trial evidence for a currently marketed product in multiple developed-country jurisdictions — materially different from Lypressin's/Ornipressin's older, discontinued/abandoned-indication evidence bases, and graded higher accordingly. 'C+' rather than higher reflects: no large cardiovascular-outcomes RCT exists to resolve the genuinely mixed BP-vs-HR tradeoff versus epinephrine in either direction; US availability/approval was not established; and pregnancy-related product guidance varies by jurisdiction (Section 17 of Stage 2BR). 'C+' rather than lower reflects that Felypressin's evidence base includes modern (2019, 2005), statistically detailed, controlled human trials, not only decades-old open-label case series.
Regulatory Context
Felypressin-containing dental local-anesthetic cartridges (Citanest DENTAL with Octapressin) are currently documented as marketed products in New Zealand, Australia, and the United Kingdom, per direct national-regulator/manufacturer sources. No FDA-approved felypressin-containing product was identified in a dedicated US-focused search for this review; current US availability is not established as either present or absent beyond that negative search result.
Research Takeaway
Felypressin (marketed under the Citanest-combination brand designation Octapressin) is a synthetic vasopressin analogue with phenylalanine at position 2 and lysine at position 8, built on the same lysine-8 backbone as Lypressin/lysine vasopressin, functioning as a non-catecholamine local vasoconstrictor in dental anesthesia.
See all 6 evidence claims →Quick Summary
Felypressin (marketed as Octapressin in Citanest-combination dental cartridges) is a synthetic, non-catecholamine vasoconstrictor currently documented as a marketed dental local-anesthetic adjuvant in New Zealand, Australia, and the United Kingdom. Its strongest evidence is controlled comparative human trials showing it raises blood pressure without raising heart rate — a genuinely mixed tradeoff against epinephrine, not a clean safety advantage. Its dominant limitations are a comparatively small clinical-trial evidence base (no large cardiovascular-outcomes RCT) and jurisdiction-specific product availability (no established US market); pregnancy-related product guidance is a secondary, jurisdiction-specific consideration — current Australian and New Zealand product information does not describe felypressin as contraindicated in pregnancy, while the current UK label advises against use in early pregnancy unless benefit outweighs risk, and a 2025 secondary review raises a mechanistic oxytocic concern that has not been established as a universal product-label finding.
Mechanism & Research Overview
Felypressin (marketed as Octapressin in Citanest-combination dental cartridges) is a synthetic, non-catecholamine vasoconstrictor currently documented as a marketed dental local-anesthetic adjuvant in New Zealand, Australia, and the United Kingdom. Its strongest evidence is controlled comparative human trials showing it raises blood pressure without raising heart rate — a genuinely mixed tradeoff against epinephrine, not a clean safety advantage. Its dominant limitations are a comparatively small clinical-trial evidence base (no large cardiovascular-outcomes RCT) and jurisdiction-specific product availability (no established US market); pregnancy-related product guidance is a secondary, jurisdiction-specific consideration — current Australian and New Zealand product information does not describe felypressin as contraindicated in pregnancy, while the current UK label advises against use in early pregnancy unless benefit outweighs risk, and a 2025 secondary review raises a mechanistic oxytocic concern that has not been established as a universal product-label finding.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Felypressin (marketed under the Citanest-combination brand designation Octapressin) is a synthetic vasopressin analogue with phenylalanine at position 2 and lysine at position 8, built on the same lysine-8 backbone as Lypressin/lysine vasopressin, functioning as a non-catecholamine local vasoconstrictor in dental anesthesia.
Sources: Clinical trial of felypressin (Octapressin) as an additive to prilocaine (Citanest) in dentistry; Cardiovascular Comparison of 2 Types of Local Anesthesia With Vasoconstrictor in Older Adults: A Crossover Study
Supported
Felypressin-containing dental local-anesthetic cartridges (Citanest DENTAL with Octapressin) are currently documented as marketed products in New Zealand, Australia, and the United Kingdom; no FDA-approved felypressin-containing product was identified in a dedicated US-focused search for this review.
Sources: NZ Medsafe Data Sheet: 3% Citanest DENTAL with Octapressin; Australian Product Information: 3% Citanest DENTAL with Octapressin; UK Summary of Product Characteristics: Citanest with Octapressin Dental
Supported
In a randomized crossover trial in adults over 65, prilocaine-felypressin raised both systolic and diastolic blood pressure at all measured timepoints without significantly changing heart rate, while lidocaine-epinephrine transiently raised systolic pressure, lowered diastolic pressure, and increased heart rate at all timepoints — a genuinely mixed cardiovascular tradeoff, not a one-directional safety advantage for either agent.
Does not establish
Evidence boundary: Neither agent is established as unqualifiedly 'safer'; the preferable agent depends on which cardiovascular parameter (blood pressure vs. heart rate) is of greater clinical concern for a given patient.
Supported
Intracervical prilocaine-felypressin significantly reduces pain during cervical biopsy and Semm-coagulator treatment compared with placebo in a randomized controlled trial, a non-dental application supporting felypressin's general local-anesthetic-potentiating role.
Does not establish
Evidence boundary: This single non-dental trial is a supplementary data point and does not establish felypressin as a general-purpose systemic or obstetric agent; Felypressin's canonical clinical identity remains dental vasoconstrictor use.
Supported
Pregnancy-related guidance for felypressin-containing Citanest/Octapressin dental products varies by jurisdiction and does not amount to a settled universal contraindication: the current Australian Product Information classifies the product ADEC Pregnancy Category A (used by a large number of pregnant women without a proven increase in malformations or other harm) and the current New Zealand Data Sheet states no specific reproductive disturbances have been reported, with neither document singling out felypressin — as opposed to prilocaine — for any pregnancy-specific warning; the current United Kingdom Summary of Product Characteristics states there is no evidence of foetal harm but, as with all drugs, the product should not be given in early pregnancy unless the expected benefit outweighs the risk — a general early-pregnancy caution applied to the combination product, not an absolute or felypressin-isolated contraindication. A 2025 secondary review (PMID 40649147) separately describes felypressin as 'contraindicated' in pregnancy based on its oxytocic/uterotonic mechanistic properties, but this statement traces, in that review's own reference list, to other narrative reviews and non-primary secondary sources reasoning inferentially from felypressin's structural similarity to vasopressin, not to direct human felypressin-pregnancy-outcome data or to any of the three national product documents reviewed here.
Does not establish
Evidence boundary: Must not be flattened into either an absolute 'Felypressin is contraindicated in pregnancy' claim or an unqualified 'Felypressin is proven safe in pregnancy' claim; the UK's early-pregnancy caution and the 2025 review's mechanistic concern remain real, product-aware, jurisdiction-specific considerations that a clinician and patient should weigh, even though none of the three jurisdictions' current product documentation frames felypressin as contraindicated.
Sources: Australian Product Information: 3% Citanest DENTAL with Octapressin; NZ Medsafe Data Sheet: 3% Citanest DENTAL with Octapressin; UK Summary of Product Characteristics: Citanest with Octapressin Dental; Review of the Safety and Clinical Considerations of Vasoconstrictor Agents in Dental Anesthesia During Pregnancy
Supported
No large cardiovascular-outcomes randomized trial was identified that resolves, in either direction, whether felypressin or epinephrine-containing local anesthetics are preferable for dental patients with cardiovascular disease; the existing controlled comparative evidence shows a mixed, parameter-dependent tradeoff, not a clear superiority finding.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Directly demonstrated in a controlled crossover RCT in older adults; the tradeoff (BP rise vs. epinephrine's HR rise) is the central cardiovascular-safety consideration for this agent.Safety Consideration
Current Australian (ADEC Category A) and New Zealand product documentation do not single out felypressin for any pregnancy-specific warning and report no specific reproductive disturbances; the current United Kingdom SPC advises the product should not be given in early pregnancy unless the expected benefit outweighs the risk — a general, product-level early-pregnancy caution, not an absolute or felypressin-specific contraindication. A 2025 secondary review (PMID 40649147) separately raises a mechanistic oxytocic/uterotonic concern, tracing in its own reference list to other narrative reviews and non-primary sources rather than direct human felypressin-pregnancy-outcome data. No authoritative current product document reviewed uses the word 'contraindicated' for felypressin in pregnancy.Safety Consideration
Existing comparative literature is small (N=22-100) and does not constitute a large outcomes RCT in high-risk cardiac patients specifically.Safety Consideration
Current product documentation is jurisdiction-specific (NZ/AU/UK); no FDA-approved product was identified. Must not be stated as globally available or as definitively unavailable in the US.
Research Areas Being Studied
Research areas discussed on this page reflect the Renal / Fluid-Balance Signaling category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Cardiovascular Comparison of 2 Types of Local Anesthesia With Vasoconstrictor in Older Adults: A Crossover Study (2019):
- A double-blind, randomized, placebo-controlled trial of prilocaine and felypressin (Citanest and Octapressin) for the relief of pain associated with cervical biopsy and treatment with the Semm coagulator (2005):
- Clinical trial of felypressin (Octapressin) as an additive to prilocaine (Citanest) in dentistry (1970):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Cardiovascular Comparison of 2 Types of Local Anesthesia With Vasoconstrictor in Older Adults: A Crossover Study | 2019 | N=22 (13 male, 9 female), mean age 77.2 years; double-blind randomized crossover, Special Care Clinic, Tokyo Medical and Dental University | Prilocaine-felypressin (P+FP) raised both systolic and diastolic blood pressure at all measured timepoints (P<.001) with no significant heart-rate change; lidocaine-epinephrine (L+AD) transiently raised systolic pressure, decreased diastolic pressure at 5/10 minutes, and increased heart rate ~10 bpm at all timepoints (P<.001). Authors' own framing: lidocaine-epinephrine may be preferable when a BP increase should be avoided; prilocaine-felypressin may be preferable when tachycardia is undesirable — a genuinely mixed, indication-dependent tradeoff, not a clean superiority result. | ||
| A double-blind, randomized, placebo-controlled trial of prilocaine and felypressin (Citanest and Octapressin) for the relief of pain associated with cervical biopsy and treatment with the Semm coagulator | 2005 | N=100 women with abnormal cervical smears, colposcopy clinic, university teaching hospital | Intracervical prilocaine-felypressin significantly reduced pain intensity during cervical biopsy and Semm-coagulator treatment versus placebo (P<.05); only 4.3%/6.7% of the active-drug group experienced moderate pain during biopsy/treatment respectively, versus up to 44.7% mild-or-worse pain in the placebo group; the active drug abolished severe pain altogether. | ||
| Clinical trial of felypressin (Octapressin) as an additive to prilocaine (Citanest) in dentistry | 1970 | Original 1970-era clinical trial introducing felypressin (Octapressin) as an additive to prilocaine (Citanest) in dentistry. |
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| NZ Medsafe Data Sheet: 3% Citanest DENTAL with Octapressin | 2019 | Current NZ product datasheet (first approved 31 Dec 1969, revised 14 May 2019; full text obtained and read directly at Stage 2BR). Section 4.6: 'It is reasonable to assume that 3% Citanest DENTAL with Octapressin has been administered to a large number of pregnant women and women of child-bearing age. No specific disturbances to the reproductive process have so far been reported.' Section 4.4's only felypressin-specific caution: 'felypressin may cause a rise in blood pressure or coronary constriction if an overdose is given' (a cardiovascular-overdose caution, not a pregnancy/oxytocic one). No oxytocic/uterine-contraction language appears anywhere in the document. | No source link available | ||
| Australian Product Information: 3% Citanest DENTAL with Octapressin | 2018 | AU-PI Revision 5.0, 15 November 2018 (full text obtained and read directly at Stage 2BR). Section 4.6: ADEC Pregnancy Category A; 'Medicines which have been taken by a large number of pregnant women and women of childbearing age without any proven increase in the frequency of malformations or other direct or indirect harmful effects on the foetus having been observed.' Safety discussion is centered on prilocaine methemoglobinemia, not felypressin. The companion Consumer Medicine Information (Dec 2025, v4) states: 'Citanest DENTAL has been widely used during pregnancy and there have been no reports of any ill effects on the baby.' | No source link available | ||
| UK Summary of Product Characteristics: Citanest with Octapressin Dental | 2016 | UK SPC (first authorised 07/07/2006, revised 14/09/2016; full text obtained and read directly at Stage 2BR). Section 4.6, quoted verbatim: 'Although there is no evidence of harm to the foetus, as with all drugs Citanest with Octapressin Dental should not be given in early pregnancy unless the benefits are considered to outweigh the risks.' This is a general, product-level early-pregnancy caution, not felypressin-isolated and not an absolute contraindication. | No source link available |
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Review of the Safety and Clinical Considerations of Vasoconstrictor Agents in Dental Anesthesia During Pregnancy | 2025 | States that felypressin, 'a vasopressin receptor agonist with known oxytocic effects, poses a clear risk of uterine stimulation and is contraindicated during pregnancy.' |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published clinical research and jurisdiction-specific regulatory/product information about Felypressin and does not provide medical advice, an individualized treatment recommendation, or dosing instructions.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated .
Follow research updates for Felypressin
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.